Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Lewy body dementia

Topic: Brain proteins, microglia and lab models

Tau proteins aggregate as cytoplasmic inclusions in a number of neurodegenerative diseases, including Alzheimer's disease and hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Over 10 exonic and intronic mutations in the tau gene have been identified in about 20 FTDP-17 families. Analyses of soluble and insoluble tau proteins from brains of FTDP-17 patients indicated that different pathogenic mutations differentially altered distinct biochemical properties and stoichiometry of brain tau isoforms. Functional assays of recombinant tau proteins with different FTDP-17 missense mutations implicated all but one of these mutations in disease pathogenesis by reducing the ability of tau to bind microtubules and promote microtubule assembly.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszolek, Z., Reed, L., Miller, B. I., et al. (1998). Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (New York, N.Y.). https://doi.org/10.1126/science.282.5395.1914

Vancouver

Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (New York, N.Y.). 1998. doi:10.1126/science.282.5395.1914. PMID: 9836646.

BibTeX

@article{hong1998-9836646,
  author  = {Hong, M. and Zhukareva, V. and Vogelsberg-Ragaglia, V. and Wszolek, Z. and Reed, L. and Miller, B. I. and Geschwind, D. H. and Bird, T. D. and others},
  title   = {{Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17}},
  journal = {Science (New York, N.Y.)},
  year    = {1998},
  doi     = {10.1126/science.282.5395.1914},
  pmid    = {9836646},
  url     = {https://doi.org/10.1126/science.282.5395.1914}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In brain tissue from people with inherited frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), different tau gene mutations changed tau's forms in different, mutation-specific ways. In lab tests on engineered tau protein, all but one of the mutations studied weakened tau's ability to bind and build microtubules, the cell's internal support tracks, which implicates this loss of function in the disease. This is laboratory and post-mortem work on a rare inherited condition. It does not test a treatment and does not directly describe typical Alzheimer's disease.

Study details

How this study scored 59/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 7 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 57 of the 96 points it could be judged on, which is 59 of 100. Total 59 of 100.57 of the 96 points we could judge = 59 of 100

Published in a top-tier journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 57 of the 96 points we could judge it on, which is 59 out of 100.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Science (New York, N.Y.))
Journal's citation record 4 / 4 Science: journal h-index 1,754 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1998 — older than 20 years, still counted
Sample size 1 / 4 17 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 1,010 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 33.7 citations a year over 30 year(s) since 1998
Impact for its field and year 5 / 6 Cited 38.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 30 other studies in this library
Still being cited 3 / 4 Cited 86 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 University of Pennsylvania: institution h-index 1,859 (OpenAlex)
Multi-centre collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 9836646)
Free to read 0 / 2 Behind a paywall — scores zero
Points 57 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 57 of the 96 points we could judge it on is 59 out of 100.
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

30 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Lewy body dementia

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →